TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: improved peer relationships
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: increased confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: arm muscle circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: arm muscle area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Dehiscence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity of VIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of VIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPV of VIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Further episodes of graft rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior Chamber (AC) inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percentage weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle conduction velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification accuracy of patients and controls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ischemia reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of cardiac death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of CHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fibrinogen reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: hsIL-6 reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative urinary excretion of L-threonate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy for prediction of RILD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: esophageal acid exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: rehabilitation length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: total rehabilitation charges
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: rate of change on functional measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean titres of serum neutralising antibody titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Defined seroprotection (neutralization titre ≥ 1:32)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Apo B/A1 ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: abnormal defecography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incident cases of CHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical Attachment Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-Reactive Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in collagen fibres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decrease in elastic fibres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in skin texture, wrinkles depth and skin coloration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Vitamin B12 intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemoglobin levels (anemia assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cardiorespiratory endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in mood disturbances
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvement in eating disturbances
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total antibiotic dispensing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trimethoprim dispensing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remifentanil requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major arterial hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Full motor recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory recovery to S1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalent vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: composite cardiac endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Combined incidence of major adverse cardiac event
Endpoint domain: Adverse events/effects
Primary endpoint: resting regional wall motion abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: stress perfusion defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: resting perfusion defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: masticatory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily breast milk intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: use of sandbags
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intra-gastric pH control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Nutrient intake levels of zinc, vitamin D, and vitamin E
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat intake percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial TAG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean alveolar bone width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean vestibular depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean density of newly formed bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteoprotegerin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: JSW deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to sustained disability progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New T2 lesion number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: BDI‐II score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission induction and maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced activation in brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Likelihood of remaining depressed
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma concentrations of 8‐epi‐PGF(2)(alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lag time for copper‐ion‐induced LDL oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in scores on the Hamilton Rating Scale for Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-advocacy post-ABI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average pupil diameter in response to pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate to postal survey of non-volunteers
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to cessation of tapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to laryngeal mask insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient discomfort during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgeon stress during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of major amputation
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of any event (major or minor amputation, or revascularization)
Endpoint domain: Mortality/survival
Primary endpoint: tolerant temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normocapnic hypoxic ventilatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: days hospitalized for cardiovascular causes within 60 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mortality during index hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: death or hospitalization at 60 days
Endpoint domain: Mortality/survival
Primary endpoint: Patients' understanding of their disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cerebral flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: closure of the PDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in general anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle pain and fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adenoid and tonsil size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal endoscopic examination scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Polysomnography (PSG) monitor results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pentraxin-3 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: self-reported mean minutes spent in moderate- and vigorous-intensity activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of individuals meeting the HEPA recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fluid retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ISF volume restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PV restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative air leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Drainage amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-testing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EVITA score indicating therapeutic advantage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Severe hypoglycemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Impaired awareness of hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hypo-distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in drug scores
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement on the animal subtask of the verbal fluency measure
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Dorsiflexion angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of implant loosening
Endpoint domain: Adverse events/effects
Primary endpoint: Mean improvement in pain scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean IOP reduction at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Complete success probability at the end of 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mild/moderate vulvar irritation
Endpoint domain: Adverse events/effects
Primary endpoint: Loss of viraemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Headache severity relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Energy Intake (EI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Agreement with care suggestions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum neuromuscular blockade (%T1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Per cent time in target range (sensor glucose 2.6‐10 mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Per cent time sensor glucose >10 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of clinically unsuspected episodes of hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HEI-2010 score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dizziness intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dizziness frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical self worth
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: perceived physical condition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: resistance training self efficacy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: self-reported 24-hour quit attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cotinine-confirmed 7-day abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: growth rate of aneurysms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adequate sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: IBS‐SSS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: IBS‐QoL data improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Decreased number of hard or lumpy stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decrease in the use of rescue medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cure rate difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in 1 Stamey grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean improvement in Urinary Incontinence Quality of Life Scale score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median time to CNS progression
Endpoint domain: Mortality/survival
Primary endpoint: Weight gain of newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stool frequency per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: OQOLI of direct caregivers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NIH-CPSI total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative ultrasound parameters (SOS and BUA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the blood concentration-time curve to 24 h (AUC(0,24 h)) for cerivastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of indurations > 14 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of stable reactions after one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Exclusive breastfeeding (EBF) practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early contraceptive use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digit Span score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No significant symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: flare (in photon counts/ms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aqueous particle concentration (particles/0.075 mm3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antenatal depression scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flexion-extension arc
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pronation-supination arc
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-surgery complications
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of anxiety disorders in adulthood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of substance misuse problems in adulthood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phase delays in response to evening light
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay in wake time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined endpoint of death, heart failure, and shock at 90 days
Endpoint domain: Mortality/survival
Primary endpoint: AUC Glucose(0-120)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: symptomatic DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: verbal instruction score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reading test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good improvement in patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibited platelet function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrinogen decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of extemporaneous compounding practices
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: survival rate at 60 days
Endpoint domain: Mortality/survival
Primary endpoint: Allogeneic transfusion requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Body fat and waist-to-height ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful termination of tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean medication usage at 12 months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Need for secondary surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: retinopathy worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: VAS scores of abdominal pain
Endpoint domain: Adverse events/effects
Primary endpoint: VAS scores of distension
Endpoint domain: Adverse events/effects
Primary endpoint: Arginine-stimulated insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Physician implementation of 'most important' recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient adherence to physician‐initiated 'most important' recommendations
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: AAER reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Integrated Pulmonary Index (IPI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes